This action relates to Abbreviated New Drug Application (“ANDA”) No. 204766, which Defendants filed or caused to be filed under 21 U.S.C. § 355(j) with the United States Food and Drug Administration (“FDA”) for approval to market a generic version of BMS’s successful Sustiva ® tablets that are sold in the United States.
Complaint for Patent Infringement
Civil Action No. 1:13-cv-04017-JBS-AMD, the Hon. Jerome B. Simandle presiding.
Filed on June 27, 2013 in the U.S. District Court for the District of New Jersey;
Patents in suit:
Complaint for Patent Infringement
Civil Action No. 1:13-cv-04017-JBS-AMD, the Hon. Jerome B. Simandle presiding.
Filed on June 27, 2013 in the U.S. District Court for the District of New Jersey;
Patents in suit:
- 6,639,071: “Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one” by Crocker et. al. Prosecuted by Walton; Kenneth R. Winokur; Melvin Camara; Valerie J.. Includes 11 claims (6 indep.). Was application 10/000,537. Granted 10/28/2003.
- 6,939,964: “Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-ben zoxazin-2-one” by Crocker et. al. Prosecuted by Walton; Kenneth R. Camara; Valerie J.. Includes 14 claims (3 indep.). Was application 10/891,749. Granted 9/6/2005.